Jcovden (previously COVID-19 Vaccine Janssen) - direct healthcare professional communication (DHPC)

adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein (Ad26.COV2-S)

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Direct healthcare professional communication (DHPC): COVID-19 Vaccine Janssen: Risk for immune thrombocytopenia (ITP) and venous thromboembolism (VTE)

Key facts

• Medicine name:
  Jcovden (previously COVID-19 Vaccine Janssen)
• Active substance:
  adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein (Ad26.COV2-S)
• Therapeutic area (MeSH):
  COVID-19 virus infection
• Procedure number:
  EMEA/H/C/005737
• Regulatory outcome:
  Variation
• DHPC type:
  Safety signal
• Human ATC codes:
  J07BX03
• Dissemination date:
  13/10/2021